NCT01423526

A Single Dose Study of DWP10292 in Healthy Male Subjects

A Dose Block-randomized, Double-blind, Placebo Controlled, Single-dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of DWP10292 After Oral Administration in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of orally administrated DWP10292 in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DWP10292	Drug: DWP10292 tablets, oral administration, single administration
DRUG	Placebo	Placebo tablets, oral administration, single administrations

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2011-08-26
• Last updated: 2014-02-25

Locations

2 sites across 1 country: South Korea